New drug can change treatment for advanced breast cancer in India
A new drug, camizestrant, promises to delay the progression of aggressive breast cancer. This treatment uses blood test-guided switching to remove drug resistance.
In short
- New drug camizestrant destroys estrogen receptors to reduce the progression of breast cancer
- In a study, switching it improved by 16 months progress-free existence
- Camizestrant was well tolerated with some treatment dissection
A new drug is showing promises to help women with camizestrant, advanced hormone-sensitive breast cancer that is ahead of the progression of the disease.
A major global study, the results of Serena -6, suggests that this next generation treatment can become a game -shineer, especially when patients feel that their body is beginning to be resistant to standard therapy.
Camizestrant belongs to a new class of drugs called selective estrogen receptor degraders (Serds).
These drugs work by directly blocking and destroying estrogen receptors, which increase the growth of many breast cancer. Unlike older remedies that only reduce estrogen levels, camizestrant serves more directly.
In Serena -6 studies, researchers tested whether on the first signals of drug resistance, switching to the camentyant, can delay the return of cancer.
Women in the test had a common type of breast cancer, called HR-positive, HER 2-negative, and already taking hormone-blocking drugs (aromatage inhibitors) with CDK 4/6 inhibitors, a combination that is considered the standard of gold for the first line treatment.
However, over time, many women stop responding to this treatment.
This is often caused by the presence of a mutation called ESR1, which makes cancer resistant to hormone-inguinal drugs.
Researchers used a simple blood test every few months to detect this mutation before the cancer deteriorated.
Once the mutation appeared, half of the women in the study were converted into camizestrant while continuing their CDK4/6 inhibitors. Others were on their original treatment.
The results were impressive: Women who switched to the camizestle had an average progress-free existence of 16 months, while for those who did not switch compared to just 9.2 months.
This means that the new drug helped them stay comparatively longer without cancer. One year in treatment, 61% of patients on camizestrant were still progressed, while compared to only 33% on chronic drugs.
Camizestrant was also well tolerated, in which very few patients were stopped due to side effects. This is important, as many women require long -term medicine and quality of life matters.
Conclusions take a big step forward in the treatment of breast cancer. Camizestrant not only provides a new way to outsource drug resistance, but also reflects the value of using blood tests to direct treatment decisions in real time.
As more data becomes available, camizestrant may soon become a standard option for women with this common and challenging form of breast cancer.
